Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer

Precllnlcal schedule dependency suggests that prolonged maintenance of low plasma levels of topotecan, a specific Inhibitor of the nuclear enzyme topoisomerase I, results in optimal antitumor activity. The pharmacokinetics and pharmacodynamics of topotecan, administered as single agent in second-lin...

Ausführliche Beschreibung